THE government decision to use Dengvaxia, the French-made anti-dengue vaccine, on Filipino grade-four schoolchildren without adequate precautionary measures, has become a scandal of monumental proportions after its manufacturer Sanofi-Pasteur recently revealed that it could cause severe, even fatal, infection on those who have not been infected before vaccination. Some 830,000 schoolchildren have reportedly been vaccinated under the anti-dengue immunization program; from January to September 2017, the Department of Health was reported to have recorded 97,287 dengue cases nationwide.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.